OCM was defined as death from other causes. Competing-risk analyses generated cumulative-incidence CSM and OCM rates according to PSM and their characteristics. The same analyses were repeated after stratifying patients in two groups: favorable (pT2 and pathologic grade group 1-3 and pN0/x) vs. adverse pathologic characteristics (pT3b/4 and/or pathologic grade group 4-5 and/or pN1). Multivariable competing-risks regression models assessed the effect of PSM on CSM after accounting for OCM.
INTRODUCTION AND OBJECTIVES: Studies on adverse effects of different androgen deprivation therapies (ADT) have previously focused on specific conditions (coronary heart disease, stroke, diabetes, fractures). None have reported effects on overall comorbidity. The objective of this study was to compare the increase in overall comorbidity among men receiving gonadotrophin releasing (GnRH) agonists with those on anti-androgen (AA) monotherapy (predominantly 150 mg bicalutamide daily) for advanced prostate cancer (PCa).
METHODS: Men on either GnRH (n[4887) or AA (n[2078) for high risk or regionally advanced PCa were selected from the Swedish Prostate Cancer Database PCBaSE 3.0, along with agematched PCa-free men for comparison. Incremental change in comorbidity was assessed in all study participants using the Charlson Comorbidity Index (CCI), calculated from 5yrs before through to 5yrs after the ADT start date. The difference in excess rate of CCI increase for men on GnRH agonists compared with men on AA monotherapy was determined using multivariable linear regression, with separate models for periods before and after starting ADT. The difference in risk of any new additional comorbidity after starting ADT was assessed using multivariable Cox proportional hazards regression.
RESULTS: The difference in excess rate of change in CCI after starting ADT was greater for men on GnRH agonists than AA monotherapy (5.7% per year; 95%CI 2.9 to 8.5% per year). No difference was evident before starting ADT. Risk of any new comorbidity following the start of ADT was also increased in men on GnRH agonists compared with AA monotherapy (HR: 1.32; 95% CI:1.20-1.44).
CONCLUSIONS: These findings suggest that the rate of increase in overall comorbidity is greater among men on GnRH agonists than men on AA monotherapy, irrespective of baseline comorbidity. Due to limitations inherent in observational studies, these results should be confirmed through randomized controlled trials to better inform treatment decisions for PCa when curative therapies are not an option. RESULTS: Overall 55 patients received aADT, 34 aADT þ aRT and 184 observation (including 96 with salvage ADT). For the entire cohort 2-year BCR-free survival, MP-free survival and overall survival rates were 33.0% (27.2-40.1%), 76.6% (71.0-82.8%) and 90.3% (86.1-94.8%). While patients with aADT þ aRT had significantly better BCR-free survival rates (78.6% vs. 29.7% (aADT) vs. 25.8% (observation), p<0.001) MP-free survival and overall survival did not differ between the groups (p>0.05). In multivariable Cox regression analyses aADTþaRT was significantly associated with a lower BCR rate (HR aADT: 5.55, HR observation: 6.15, both p<0.001), while there was no effect on MP or overall mortality (p>0.05).
CONCLUSIONS: In patients with high lymph node burden, combination of aADTþaRT might lower BCR risk. However, further oncological outcomes, namely MP and overall mortality, were not affected by the addition of radiation therapy.
Source of Funding: none

MP22-13 IMPACT OF RELATIONAL COHESION AND SEXUALITY ON THE QUALITY OF LIFE OF PATIENTS TREATED WITH GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST FOR PROSTATE CANCER: FINAL ANALYSIS OF THE EQUINOXE STUDY
St ephane Droupy*, Nîmes, France; Marie-H el ene Colson, Marseille, France; Nathalie Pello-Leprince-Ringuet, Val erie Perrot, Boulogne-Billancourt, France; Aurelien Descazeaud, Limoges, France INTRODUCTION AND OBJECTIVES: The first few months of treatment for prostate cancer (PCa) are a difficult time for a couple. The degree of relational cohesion could have an effect on the experience of the disease. We analyzed the factors influencing the evolution of quality of life (QoL) in patients with PCa treated with hormone therapy for 6 months.
METHODS: French prospective, multicenter, longitudinal and non-interventional study (NCT02630641). Urologists recruited partnerpatient couples with PCa for whom hormone therapy was indicated. Data were collected at inclusion and after 6 months of treatment, on CONCLUSIONS: The men who benefited the most from hormone therapy in terms of QoL were those who suffered from symptoms and those who had no sexual activity at baseline. The influence of the cohesion within the couple on the evolution of the QoL is not confirmed in multivariate analysis. Recent randomized trials have also demonstrated benefit from combination docetaxel with ADT for men with naive metastatic cancer. The use neoadjuvant chemo-hormonal therapy in conjunction with local consolidative treatment in this setting, however, has not previously been described. We present the initial surgical outcomes of a novel protocol.
Source of Funding: Ipsen Pharma
MP22-14 DEFINITIVE THERAPY FOR MEN WITH NEWLY-DIAGNOSED OLIGOMETASTATIC PROSTATE CANCER: INITIAL SURGICAL OUTCOMES FROM A PHASE II STUDY
METHODS: A phase II study conducted at our institution began accruing patients in 2016. Men with newly diagnosed oligometastatic prostate cancer (T1-4, N0-1, M1a-b) consisting of 5 metastatic lesions were treated with the following: (1st) systemic therapy with up to 6 months of neoadjuvant ADT and 6 cycles of docetaxelþADT, (2nd) consolidation with radical prostatectomy (RP) AE adjuvant radiation therapy (XRT), and (3rd) AE stereotactic radiation (SBRT) to oligometastatic lesions.
RESULTS: To date, 18 patients have enrolled in the study: 17 have undergone RP and 1 is currently receiving neoadjuvant systemic therapy. For men undergoing surgery, median age was 58.0 years (IQR 55.0-64.0) with median follow-up of 10.1 months (IQR 4.1-13.2). Patients had a median 2 sites of metastases (IQR 1.0-3.0) and PSA 15.9 (IQR 7.2-66; range, 3.6-953) at diagnosis. Patients received a median of 12 months of ADT and 4 cycles of Docetaxel; median PSA after systemic therapy was 0.6 (IQR 0.2-1.6). Median operative time, blood loss, and length of hospitalization were 177.5 min ), 200 ml (IQR 137.5-450.0), and 1 day (IQR 1.0-1.3), respectively. Six patients underwent open and 11 underwent robotassisted RP with a 23.6% perioperative transfusion rate overall -2 patients in the open group and 2 in the robot group. One patient (5.9%) experienced a Clavien grade II complication (hematuria with UTI); the other three experienced Clavien grade III complications (hematuria in 1 patient, bladder neck contractures requiring dilation in 2 patients). The majority (13 patients, 76.5%) had !ypT3a disease and 5 (47.1%) had positive surgical margins. Lymph node dissection yielded a median 13.5 nodes 3), and 7 (41.1%) men had lymph node metastases. Seven patients (41.1%) have undergone adjuvant XRT and 9 (52.9%) have completed SBRT, to date. All 17 patients thus far have obtained post-RP PSA levels, all of which are undetectable.
CONCLUSIONS: The combination of neoadjuvant chemohormonal therapy with definitive local therapy and SBRT for patients with oligometastatic prostate cancer appears feasible based on initial surgical outcomes. This management paradigm presents a possible future option for the treatment of men with oligometastatic prostate cancer. Longer-term safety, survival, and functional outcomes from this study are forthcoming.
Source of Funding: None
MP22-15
INTRODUCTION AND OBJECTIVES: Androgen deprivation therapy (ADT) for the treatment of prostate cancer has been shown, albeit not consistently, to be related to specific consequences such as incident depression. The presence of depressive symptoms in patients with advanced disease eligible for ADT is less well understood. The current study was undertaken to estimate the prevalence and predictors of depression in a contemporary sample of patients beginning ADT.
METHODS: Data from the current study were drawn from the RADICAL PC study, a parent prospective cohort study conducted across 13 sites in Canada. Men with prostate cancer initiating ADT for the first time were recruited. Depressive symptoms were evaluated using the 9 item version of the Patient Health Questionnaire (PHQ-9). A score of 8 or higher on this scale represents clinically relevant depressive symptoms. To evaluate predictors of depressive symptoms, a logistic regression model was constructed including biological, psychological, and social predictor variables. RESULTS: Data from 407 patients were available at the time of this analysis. Of these, 43 (10.6%) endorsed clinically significant burden of depressive symptoms. Two variables were identified as independent predictors of depression -poor functional status (OR[5.18, p<0 .001) increased depression risk, whereas being retired was found to be protective (OR[0.37, p[0.03) . Indicators of advanced disease (e.g. presence of metastatic disease) were not associated with depression in either univariate or multivariate models.
CONCLUSIONS: Our multi-centre study of depressive symptoms among prostate cancer patients starting ADT shows that these symptoms are already present in a sizeable sample of men. These do not seem to be affected by disease-related indicators, but rather are better predicted by psychosocial variables. Clinicians should be suspicious of poor psychological functioning especially among those prostate cancer patients with poorer functional status. Moving forward, it will be important to document the incidence and change in depressive symptoms as these patients begin ADT and are followed prospectively.
